Hepatorenal syndrome epidemiology and demographics
|
Hepatorenal syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hepatorenal syndrome epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Hepatorenal syndrome epidemiology and demographics |
|
Hepatorenal syndrome epidemiology and demographics in the news |
|
Risk calculators and risk factors for Hepatorenal syndrome epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Epidemiology and Demographics
It is estimated that 39% of patients with cirrhosis and ascites will develop hepatorenal syndrome within five years of the onset of their disease.[1] The prognosis of these patients is grim with untreated patients having an extremely short survival,[2][1][3] and with the severity of liver disease (as evidenced by the MELD score) now believed to determine outcome.[4] Some patients without cirrhosis develop hepatorenal syndrome, with an incidence of about 20% seen in one study of ill patients with alcoholic hepatitis.[5]
References
- ↑ 1.0 1.1 Invalid
<ref>tag; no text was provided for refs namedGinesCohort - ↑ Invalid
<ref>tag; no text was provided for refs namedArroyo1 - ↑ Invalid
<ref>tag; no text was provided for refs namedFloWo - ↑ Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jimenez W, Arroyo V, Rodes J, Gines P. MELD score and clinical type predict prognosis in hepatorenal syndrome: Relevance to liver transplantation. Hepatology 2005 Jun;41(6):1282-9. PMID 15834937
- ↑ Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000 Dec;119(6):1637-48. PMID 11113085.